<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240834</url>
  </required_header>
  <id_info>
    <org_study_id>2019XK320061</org_study_id>
    <nct_id>NCT04240834</nct_id>
  </id_info>
  <brief_title>Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention</brief_title>
  <acronym>LD-ASPIRIN</acronym>
  <official_title>Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation,Single-center, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Wai Hospital, Beijing, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose
      Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary
      syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention
      (PCI) and stent implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center
      Study. There will be 1220 ACS patients at high risk for ischemic events after successful PCI
      with implantation of at least one drug eluting stent who will be enrolled in Fuwai Hospital,
      China. Then those included subjects will be randomized to either Ticagrelor plus low-dose
      Aspirin (50mg daily, LD group) or Ticagrelor plus regular dose Aspirin (75mg daily, control
      group) for 12 months. The primary endpoint of the current study is to determine the impact of
      low-dose Aspirin plus Ticagrelor versus standard DAPT for 12 months on major adverse cardiac
      and cerebral events (MACCEs), and the secondary endpoint is to determine whether the protocol
      of low dose Aspirin plus Ticagrelor reduces bleeding events, sufficiently inhibits platelet
      function, and increases the medication adherence among the included patients. In summary, the
      present study is to provide new evidence and strategy about the anti-platelet protocol for
      ACS patients at high risk for ischemia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebral events (MACCEs)</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Number of participants with a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding episode (Key secondary endpoint)</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Number of participants with major bleeding(Bleeding Academic Research Consortium (BARC) types ≥3) and/or minor bleeding(Bleeding Academic Research Consortium (BARC) types 0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet function</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Platelet inhibition, blood level and urine level of thromboxaneB2(TXB2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding-related withdrawal</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1220</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Interventional Cardiology</condition>
  <arm_group>
    <arm_group_label>LD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>LD group</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>LD group</arm_group_label>
    <other_name>Brilinta/Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACS patients at high risk for ischemic events after successful PCI with implantation
             of at least one drug eluting stent

          -  Able and willing to provide informed consent and participate in 12 months follow-up
             period

          -  Able to receive DAPT treatment

          -  Enrollment into the study will require meeting at least one angiographic inclusion and
             none of the exclusion criteria.

        Angiographic Inclusion Criteria:

          1. LM lesion requiring stents

          2. Proximal LAD lesion(s) requiring stents

          3. Bypass grafts lesion(s) requiring stents

          4. Overall stent length ≥60 mm

          5. History of in-stent thrombosis

          6. Bifurcation lesions requiring at least 2 stents

          7. Over two vessels lesions requiring stents

          8. Calcified target lesion(s) requiring atherectomy

          9. The intraoperative occurrence of no-reflow or slow-flow

         10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow
             restoration (at least TIMI 3)

        Exclusion Criteria:

          -  Need for chronic oral anticoagulation

          -  With cardiomyopathy（HCM/DCM/RCM）

          -  With severe ventricular arrhythmia requiring ICD implantation

          -  With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart
             disease)

          -  With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）

          -  With hematological disorders（thrombocytopenia, severe anemia, leukaemia）

          -  With severe liver disease or kidney failure

          -  With malignant tumor

          -  With cognitive impairment

          -  Unable or unwilling to provide informed consent or undergo follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiyan Qian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiyan Qian, MD, PhD</last_name>
    <phone>+8613811386143</phone>
    <email>ahqhy712@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiyao Wei</last_name>
    <phone>+8615521192379</phone>
    <email>weizhiyaoyx@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haiyan Qian, MD, PhD</last_name>
      <phone>+8613811386143</phone>
      <email>ahqhy712@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fu Wai Hospital, Beijing, China</investigator_affiliation>
    <investigator_full_name>Qian Haiyan</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ACS</keyword>
  <keyword>PCI</keyword>
  <keyword>DAPI</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

